ORIGINAL RESEARCH
Assessing Effects of Treatment With Lisdexamfetamine Dimesylate for Pediatric ADHD Using a Parental Survey
D. Antonucci, C. Kunins, M. Manos, F.A. López, D.L. Kerney

Clinical Features and Treatment Characteristics of Compulsive Hoarding in Japanese Patients with Obsessive-Compulsive Disorder
H. Matsunaga, K. Hayashida, N. Kiriike, T. Nagata, D.J. Stein

REVIEW ARTICLE
Duration of Untreated Psychosis and Duration of Untreated Illness: New Vistas
Bernardo Dell’Osso, A.C. Altamura

CASE REPORT
Cerebrotendinous Xanthomatosis Presenting with Severe Externalized Disorder: Improvement After One Year of Treatment with Chenodeoxycholic Acid
O. Bonnot, M.J. Fraidakis, R. Lucanto, D. Chauvin, N. Kelley, M. Plaza, O. Dubourg, O. Lyon-Caen, F. Sedel, D. Cohen

TRENDS IN PSYCHOPHARMACOLOGY
Methylated Spirits: Epigenetic Hypotheses of Psychiatric Disorders
S.M. Stahl
While no medication can guarantee a patient will be relapse-free, using long-acting, professionally administered medication can help you recognize a missed dose and intervene.
FOR ACUTE AND MAINTENANCE TREATMENT OF SCHIZOPHRENIA

RETHINK THE WAY YOU TREAT

NEW ONCE-MONTHLY INVEGA® SUSTENNA®
paliperidone palmitate extended-release injectable suspension

ACT EARLIER
WITH NEW ONCE-MONTHLY INVEGA® SUSTENNA®

- Once-monthly dosing
- Demonstrated safety and tolerability profile
- Significantly delayed time to relapse in the longer-term maintenance study

° Reported in 4 fixed-dose, double-blind, placebo-controlled studies (N=1803).
° Reported in the longer-term maintenance study (N=849).

Potential for Cognitive and Motor Impairment: Somnolence, sedation, and dizziness were reported as adverse reactions in subjects treated with INVEGA® SUSTENNA®. INVEGA® SUSTENNA® has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that INVEGA® SUSTENNA® does not affect them adversely, and should use caution when operating machinery.

- Seizures: INVEGA® SUSTENNA® should be used cautiously in patients with a history of seizures or with conditions that potentially lower seizure threshold.
- Suicide: The possibility of suicide attempt is inherent in schizophrenia. Close supervision of high-risk patients should accompany drug therapy.
- Administration: For intramuscular injection only. Care should be taken to avoid inadvertent injection into a blood vessel.
- Commonly Observed Adverse Reactions for INVEGA® SUSTENNA®: The most common adverse reactions in clinical trials in patients with schizophrenia (>5% and twice placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia and extrapyramidal disorder.


Please see accompanying brief summary of full Prescribing Information for INVEGA® SUSTENNA®.
Visit www.invegasustenna.com for more information.
INVEGA® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

Brief Summary

BEFORE PRESCRIBING INVEGA® SUSTENNA™, PLEASE SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking typical antipsychotic drugs, revealed a risk of death in drug-treated patients of 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® SUSTENNA™ (paliperidone palmitate) is not approved for the treatment of patients with dementia-related psychosis. [See Warnings and Precautions]

INVEGA® SUSTENNA™ (paliperidone palmitate) is indicated for the acute and maintenance treatment of schizophrenia in adults [see Clinical Studies (14) in full].

CONTRAINDICATIONS

Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. Paliperidone palmitate is converted to paliperidone, which is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the INVEGA® SUSTENNA™ formulation.

WARNINGS AND PRECAUTIONS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. INVEGA® SUSTENNA™ (paliperidone palmitate) is not approved for the treatment of dementia-related psychosis [see Boxed Warning].

Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients With Dementia-Related Psychosis: In placebo-controlled trials with paliperidone and INVEGA® SUSTENNA™, stroke, defined as a cerebrovascular adverse event (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. Paliperidone and INVEGA® SUSTENNA™ are not marketed at the time these studies were performed and are not approved for the treatment of patients with dementia-related psychosis [see also Boxed Warning and Warnings and Precautions].

Neuroleptic Malignant Syndrome: A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including paliperidone. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological管理制度 for complicated NMS.

If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.

QT Prolongation: Paliperidone causes a modest increase in the corrected QT (QTc) interval. The use of paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class 3 (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

INVEGA® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

Certain circumstances may increase the risk of the occurrence of torsade de points and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.

The effects of paliperidone on the QT interval were evaluated in a double-blind, randomized, placebo-controlled (moxifloxacin 400 mg single dose), multicenter QT study in adults with schizophrenia and schizoaffective disorder, and in three placebo- and active-controlled 6-week, fixed-dose efficacy trials in adults with schizophrenia.

In the QT study (n = 141), the 8 mg dose of immediate-release oral paliperidone (n=50) showed a mean placebo-subtracted increase from baseline in QTcLD of 12.3 msec (90% CI: 6.8; 15.8) on day 8 at 1.5 hours post-dose. only one subject in the oral paliperidone 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec). The four fixed-dose efficacy studies of oral paliperidone extended release, placebo-controlled in the general population. Given these confounders, the relationship subject in the oral paliperidone 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec). The four fixed-dose efficacy studies of INVEGA® SUSTENNA™, no subject experienced a change in QTcLD exceeding 60 msec and no subject had a QTcLD value > 500 msec at any timepoint. In the main study, no subject had a QTcLD change > 60 msec, and one subject had a QTcLD value of 507 msec (Bazzett’s QT corrected interval [QTcB] > 483 msec); this subject also had a heart rate of 45 beats per minute.

Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The development of tardive dyskinesia should be monitored carefully in all patients who are treated with antipsychotic drugs. The syndrome is more common in patients treated for a long time at high dosage levels. It is more likely to occur in the geriatric population and less likely to occur in patients treated with the atypical antipsychotic drugs than with the conventional antipsychotic drugs. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome can develop after relatively brief treatment periods at low doses, although this is uncommon. There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown. Given these considerations, INVEGA® SUSTENNA™ should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to be associated with antipsychotic drug use and for whom it is judged to be safer than the risks of untreated psychosis. The smallest effective dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient treated with INVEGA® SUSTENNA™, drug discontinuation should be considered. However, some patients may require treatment with INVEGA® SUSTENNA™ despite the presence of the syndrome.

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with all atypical antipsychotics. These cases were, for the most part, seen in post-marketing clinical use and epidemiologic studies, not in clinical trials, and there have been few reports of hyperglycemia or diabetes in trial subjects treated with INVEGA® SUSTENNA™. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with atypical antipsychotics.

In patients with established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glycemic control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotic drugs should be monitored for symptoms of hypoglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
INVEGA® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

Seizures: In the four fixed-dose double-blind placebo-controlled studies, <1% (1/1293) of subjects treated with INVEGA® SUSTENNA™ in the recommended dose range of 39 mg to 234 mg experienced an adverse event of convulsion compared with <1% (1/510) of placebo-treated subjects who experienced an adverse event of grand mal convulsion. Like other antipsychotic drugs, INVEGA® SUSTENNA™ should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer’s dementia. INVEGA® SUSTENNA™ and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

Suicide: The possibility of suicide attempt is inherent in psychotic illnesses, and close supervision of high-risk patients should accompany drug therapy.

Orthostatic Hypotension and Syncope:

In clinical trials comparing INVEGA® SUSTENNA™ with other antipsychotic drugs, In the four fixed-dose double-blind placebo-controlled trials (pooled data), the proportions of subjects meeting a weight gain criterion of >7% of body weight were 6%, 9%, and 10% in the INVEGA® SUSTENNA™ 39 mg, 78 mg, and 156 mg groups, respectively, compared with 2% in the placebo group. In the 5-week, fixed-dose, double-blind, placebo-controlled trial, 8% and 6% in the INVEGA® SUSTENNA™ 78 mg and 156 mg groups respectively, met this criterion compared with 4% in the placebo group.

During the 33-week open-label period (9-week flexible-dose transition phase followed by a 24-week maintenance phase fixed-dose and minimum 12-week fixed dose) of the maintenance trial, 12% of INVEGA® SUSTENNA™-treated subjects met this criterion; the mean (SD) weight change from double-blind baseline was +0.5 kg for INVEGA® SUSTENNA™ compared with -1.0 kg for placebo. Similar results were observed in the open-label extension phase of this study.

Hyperprolactinemia: Like other drugs that antagonize dopamine D2 receptors, paliperidone elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

Hyperprolactinemia, regardless of etiology, may suppress hypothalamic GnRH, resulting in reduced gonadal steroidogenesis. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadotropic hypogonadism may result in a decrease in bone density. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. An increase in the incidence of pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats (see Preclinical Safety Data).

INVEGA® SUSTENNA™ 39 mg, 78 mg, and 156 mg groups, respectively. In the two 13-week, fixed-dose, double-blind placebo-controlled trials (pooled data), the proportion of subjects meeting a weight gain criterion of >7% of body weight were 6%, 9%, and 10% in the INVEGA® SUSTENNA™ 39 mg, 78 mg, and 156 mg groups, respectively, compared with 2% in the placebo group. In the 5-week, fixed-dose, double-blind, placebo-controlled trial, 8% and 6% in the INVEGA® SUSTENNA™ 78 mg and 156 mg groups respectively, met this criterion compared with 4% in the placebo group.

Orthostatic Hypotension and Syncope: Paliperidone can induce orthostatic hypotension and syncope in some patients because of its alpha-blocking activity. Syncope was reported in <1% (4/1293) of subjects treated with INVEGA® SUSTENNA™ in the recommended dose range of 39 mg to 234 mg in the four fixed-dose, double-blind, placebo-controlled trials compared with 0% (0/510) of subjects treated with placebo. In the four fixed-dose efficacy trials, the proportion of INVEGA® SUSTENNA™-treated subjects who experienced an orthostatic event was <1% (2/2129) of INVEGA® SUSTENNA™-treated subjects compared to 0% (0/510) with placebo. Incidences of orthostatic hypotension and syncope in the long-term studies were similar to those observed in the short-term studies.

INVEGA® SUSTENNA™ should be used with caution in patients with known cardiovascular disease (e.g., a heart history, failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). Monitoring of orthostatic vital signs should be considered in patients who are at risk for hypotension.

Leukopenia, Neutropenia, and Agranulocytosis: As a class effect, INVEGA® SUSTENNA™ and other antipsychotics have been reported temporally related to antipsychotic agents, including INVEGA® SUSTENNA™, an oral form of paliperidone. Agranulocytosis has also been reported.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Paliperidone plasma exposure of a clinically significant low WBC or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of INVEGA® SUSTENNA™ should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm^3) should discontinue INVEGA® SUSTENNA™ and have their WBC followed until recovery.

Potential for Cognitive and Motor Impairment: Somnolence, sedation, and dizziness were reported as adverse reactions in subjects treated with INVEGA® SUSTENNA™ (see Adverse Reactions). Antipsychotics, including INVEGA® SUSTENNA™, have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that paliperidone therapy does not adversely affect them.

Monitoring: Laboratory Tests: No specific laboratory tests are recommended.

ADVERSE REACTIONS

The following are discussed in more detail in other sections of the labeling:

- Increased mortality in elderly patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions]
- Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis [see Warnings and Precautions]
- Neuroleptic malignant syndrome [see Warnings and Precautions]
- QT prolongation [see Warnings and Precautions]
- Tardive dyskinesia [see Warnings and Precautions]
- Hyperglycemia and diabetes mellitus [see Warnings and Precautions]
- Weight gain [see Warnings and Precautions]
- Orthostatic hypotension and syncope [see Warnings and Precautions]
- Leukopenia, neutropenia, and agranulocytosis [see Warnings and Precautions]
- Potential for cognitive and motor impairment [see Warnings and Precautions]
- Seizures [see Warnings and Precautions]
- Dysphagia [see Warnings and Precautions]
- Suicide [see Warnings and Precautions]
- Priapism [see Warnings and Precautions]
- Thrombotic Thrombocytopenic Purpura [see Warnings and Precautions]
- Disruption of body temperature regulation [see Warnings and Precautions]
- Avoidance of inadvertent injection into a blood vessel [see Warnings and Precautions]
- Increased sensitivity in patients with Parkinson’s disease or those with dementia with Lewy bodies [see Warnings and Precautions]
INVIGE® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

Adverse Reactions Observed During the Premarketing Evaluation of INVIGE® SUSTENNA™ Not Listed in Table 1: The following additional adverse reactions occurred in INVIGE® SUSTENNA™-treated subjects in the above four fixed-dose, double-blind, placebo-controlled trials, in the double-blind phase of the maintenance trial, 5 or in INVIGE® SUSTENNA™-treated subjects who participated in other Phase 3 trials, and were not reported in Table 1. They were determined to be adverse reactions based upon reasons to suspect causality such as timing of onset or termination with respect to drug use, plausibility in light of the drug's known pharmacology, occurrence at a frequency above that expected in the treated population or occurrence of an event typical of drug-induced adverse reactions.

Cardiac disorders: bradycardia, bundle branch block, postural orthostatic tachycardia syndrome, tachycardia
Ear and labyrinth disorders: vertigo
Endocrine disorders: hyperprolactinemia
Eye disorders: optic atrophy, vision blurred
Gastrointestinal disorders: salivary hypersecretion, stomach discomfort
Investigations: blood cholesterol increased, blood glucose increased
Metabolism and nutrition disorders: decreased appetite, increased appetite
Nervous system disorders: confusion, dizziness postural, drooling, dysarthria, dysthenia, dystonia, gait ataxia, hypokinesia, hypotonic, hypotonic/emergency, hypothermia, incontinence, intermittent claudication, leg pain, limb weakness, neuropathy, paresthesia, peripheral neuropathy, pinnick, pinnick hyperactivity, syncope
Psychiatric disorders: restlessness
Reproductive system and breast disorders: amenorrhea, erectile dysfunction, gynaecomastia, menstruation irregular, sexual dysfunction
Skin and subcutaneous tissue disorders: pruritus generalized, rash
Vascular disorders: orthostatic hypotension

Discontinuations Due to Adverse Events: The percentages of subjects who discontinued due to adverse events in the four fixed-dose, double-blind, placebo-controlled trials were 5.0% and 7.8% in INVIGE® SUSTENNA™- and placebo-treated subjects, respectively.

Dose-Related Adverse Reactions: Based on the pooled data from the four fixed-dose, double-blind, placebo-controlled trials, among the adverse reactions that occurred at ≥2% incidence in the subjects treated with INVIGE® SUSTENNA™, only akathisia increased with dose. Hyperprolactinemia also exhibited a dose relationship, but did not occur at ≥2% incidence in INVIGE® SUSTENNA™-treated subjects from the four fixed-dose studies.

Demographic Differences: An examination of population subgroups in the double-blind placebo-controlled trials did not reveal any evidence of differences in safety on the basis of age, gender, or race alone; however, there were few subjects ≥65 years of age.

Extrapyramidal Symptoms (EPS): Pooled data from the two double-blind, placebo-controlled, 13-week, fixed-dose trials provided information regarding treatment-emergent EPS. Several methods were used to measure EPS: (1) the Simpson-ANGUS global score (mean change from baseline or score at the end of trial) which broadly evaluates Parkinsonism, (2) the Barnes Akathisia Rating Scale global clinical rating score (mean change from baseline or score at the end of trial which evaluates akathisia), (3) use of anticholinergic medications to treat emergent EPS, (4) the Abnormal Involuntary Movement Scale scores (mean change from baseline or scores at the end of trial) (Table 2), and (5) incidence of spontaneous reports of EPS (Table 3).

Table 2. Treatment-Emergent Extrapyramidal Symptoms (EPS) Assessed by Incidence of Rating Scales and Use of Anticholinergic Medication: Scale followed by Percentage of Subjects Placebo (N=262) first, INVIGE® SUSTENNA™ 39 mg (N=130) second, Parkinsonism and akathisia assessed by incidence of rating scales which were higher in the 6, 5, Dyskinesia 3, 4, 6, 4, Use of Anticholinergic Medications 12, 10, 12, 11.4 For Parkinsonism, percent of subjects with Simpson-ANGUS Rating Scale global score ≥ 0.3 at endpoint (Total score defined as total sum of items score divided by the number of items) 4 For Akathisia, percent of subjects with Barnes Akathisia Rating Scale global score ≥ 0.3 at endpoint 4 For Dyskinesia, percent of subjects with a score ≥ 3 or on any of the first 7 items or a score ≥ 2 on two or more of any of the first 7 items of the Abnormal Involuntary Movement Scale at endpoint 4 Percent of subjects who received anticholinergic medications to treat emergent EPS.

Dyskinesia group includes: Dyskinesia, choreathetosis, muscle twitching, myoclonus, tardive dyskinesia
Dystonia group includes: Dystonia, muscle spasms

The results across all phases of the maintenance trial exhibited comparable findings. In the 9-week, fixed-dose, double-blind, placebo-controlled trial, the proportions of Parkinsonism and akathisia assessed by incidence of rating scales were higher in the INVIGE® SUSTENNA™ 156 mg group (18% and 11%, respectively) than in the INVIGE® SUSTENNA™ 39 mg group (18% and 11%, respectively).
INVEGA® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

INVEGA® SUSTENNA™ 78 mg group (9% and 5%, respectively) and placebo group (7% and 4%, respectively).

In the 13-week study involving 234 mg initiation dosing, the incidence of any treatment-emergent EPS-related adverse events was similar to that of the placebo group (8%), but exhibited a dose-related pattern with 6%, 10%, and 11% in the INVEGA® SUSTENNA™ 254/39 mg, 234/156 mg, and 234/234 mg groups, respectively. Hyperkinesia was the most frequent category of EPS-related adverse events in this study, and was reported at a similar rate between the placebo (4.9%) and INVEGA® SUSTENNA™ 234/156 mg (4.8%) and 234/234 mg (5.5%) groups, but at a lower rate in the 234/39 mg group (1.3%).

Dystonia: Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Laboratory Test Abnormalities: In the pooled data from the two double-blind, placebo-controlled, 13-week, fixed-dose trials, a between-group comparison revealed no medically important differences between INVEGA® SUSTENNA™ and placebo in the proportions of subjects experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no differences between INVEGA® SUSTENNA™ and placebo in the incidence of discontinuations due to changes in hematology, urinalysis, or serum chemistry, including mean changes from baseline in fasting glucose, insulin, c-peptide, triglyceride, HDL, LDL, and total cholesterol measurements. However, INVEGA® SUSTENNA™ was associated with increases in serum prolactin (see Warnings and Precautions). The results from the 13-week study involving 234 mg initiation dosing, the 9-week, fixed-dose, double-blind, placebo-controlled trial, and the double-blind phase of the maintenance trial exhibited comparable findings.

Pain Assessment and Local Injection Site Reactions: In the pooled data from the two 13-week, fixed-dose, double-blind, placebo-controlled trials, the mean intensity of injection pain reported by subjects using a visual analog scale (0 = no pain to 100 = unbearable pain) decreased in all treatment groups from the first to the last injection (placebo: 10.9 to 9.8; 39 mg: 10.3 to 7.7; 78 mg: 10.0 to 9.2; 156 mg: 11.1 to 8.8). The results from both the 9-week, fixed-dose, double-blind, placebo-controlled trial and the double-blind phase of the maintenance trial exhibited comparable findings.

Adverse Reactions Reported With Oral Paliperidone: The following is a list of additional adverse reactions that have been reported with oral paliperidone in subjects with schizophrenia:

Cardiac disorders: atrioventricular block first degree, palpitations, sinus arrhythmia
Gastrointestinal disorders: abdominal pain, swollen tongue
General disorders and administration site conditions: edema
Immune system disorders: anaphylactic reaction
Musculoskeletal and connective tissue disorders: muscle rigidity
Nervous system disorders: tremor
Reproductive system and breast disorders: priapism, breast discharge
Vascular disorders: ischemia

Adverse Reactions Reported With Risperidone: Paliperidone is the major active metabolite of risperidone. Adverse reactions reported with oral risperidone and risperidone long-acting injection can be found in the ADVERSE REACTIONS sections of the package inserts for those products.

DRUG INTERACTIONS

Since paliperidone palmitate is hydrolyzed to paliperidone [see Clinical Pharmacology (12.3) in full PI], results from studies with oral paliperidone should be taken into consideration when assessing drug-drug interaction potential.

Potential for Other Drugs to Affect Other Drugs: Given the primary CNS effects of paliperidone [see Adverse Reactions], INVEGA® SUSTENNA™ should be used with caution in combination with other centrally acting drugs and alcohol. Paliperidone may antagonize the effect of levodopa and other dopaminergic agonists. Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when INVEGA® SUSTENNA™ is administered with other therapeutic agents that have this potential [see Warnings and Precautions].

Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.

Paliperidone is a weak inhibitor of F-glycoprotein (F-gp) at high concentrations. No in vivo studies are available, and therefore the clinical relevance is unknown.

Potential for Other Drugs to Affect INVEGA® SUSTENNA™: Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.

Co-administration of oral paliperidone extended release once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. On initiation of carbamazepine, the dose of INVEGA® SUSTENNA™ should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of INVEGA® SUSTENNA™ should be re-evaluated and decreased if necessary.

Paliperidone is metabolized to a limited extent by CYP2D6 [see Clinical Pharmacology (12.3) in full PI]. In an interaction study in healthy subjects in which a single 3 mg dose of oral paliperidone extended release was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4.3, 30.3) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.

Co-administration of a single dose of an oral paliperidone extended-release 12 mg tablet with divalproex sodium extended-release tablets (two 500 mg tablets once daily at steady-state) resulted in an increase in approximately 50% in the Cmax and AUC of paliperidone. Although this interaction has not been studied with INVEGA® SUSTENNA™, a clinically significant interaction would not be expected between divalproex sodium and INVEGA® SUSTENNA™ intramuscular injection.

USE IN SPECIFIC POPULATIONS

Pregnancy: Pregnancy Category C: There were no treatment-related effects on the offspring when pregnant rats were injected intramuscularly with paliperidone palmitate during the period of organogenesis at doses up to 160 mg/kg, which is 10 times the maximum recommended human 234 mg dose of INVEGA® SUSTENNA™ on a mg/m² basis.

Studies in pregnant rats and rabbits in which paliperidone was given orally during the period of organogenesis, there were no increases in fetal abnormalities up to the highest doses tested (10 mg/kg/day in rats and 5 mg/kg/day in rabbits), which are each 8 times the maximum recommended human dose [12 mg/day] of orally administered paliperidone (INVEGA®) on a mg/m² basis.

In rat reproduction studies with risperidone, which is extensively converted to paliperidone, this compound is also self-limited. It is not known whether paliperidone, when taken near the end of pregnancy, will lead to similar neonatal signs and symptoms.

Labor and Delivery: The effect of INVEGA® SUSTENNA™ on labor and delivery in humans is unknown.

Nursing Mothers: In animal studies with paliperidone and in human studies with risperidone, paliperidone was excreted in the milk. Therefore, women receiving INVEGA® SUSTENNA™ should not breast feed infants.

Pediatric Use: Safety and effectiveness of INVEGA® SUSTENNA™ in patients < 18 years of age have not been established.

Geriatric Use: Clinical studies of INVEGA® SUSTENNA™ did not include sufficient numbers of elderly subjects and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with renal impairment [see Clinical Pharmacology (12.3) in full PI], who should be given reduced doses. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.5) in full PI].
INVEGA® SUSTENNA™ (paliperidone palmitate) Extended-Release Injectable Suspension

Renal Impairment: INVEGA® SUSTENNA™ has not been systematically studied in patients with renal impairment [see Clinical Pharmacology (12.3) in full PI]. For patients with mild renal impairment (creatinine clearance > 50 mL/min to < 80 mL/min), recommended initiation of INVEGA® SUSTENNA™ is with a dose of 156 mg on treatment day 1 and 117 mg one week later, both administered in the deltoid muscle. Thereafter, follow with monthly injections of 78 mg in either the deltoid or gluteal muscle.

INVEGA® SUSTENNA™ is not recommended in patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min).

Hepatic Impairment: INVEGA® SUSTENNA™ has not been studied in patients with hepatic impairment. Based on a study with oral paliperidone, no dose adjustment is required in patients with mild or moderate hepatic impairment. Paliperidone has not been studied in patients with severe hepatic impairment.

DRUG ABUSE AND DEPENDENCE

Controlled Substance: INVEGA® SUSTENNA™ (paliperidone) is not a controlled substance.

Abuse: Paliperidone has not been systematically studied in animals or humans for its potential for abuse.

Dependence: Paliperidone has not been systematically studied in animals or humans for its potential for tolerance or physical dependence.

OVERDOSAGE

Human Experience: No cases of overdose were reported in premarketing studies with INVEGA® SUSTENNA™. Because INVEGA® SUSTENNA™ is to be administered by health care professionals, the potential for overdose by patients is low.

While experience with paliperidone overdose is limited, among the few cases of overdose reported in premarketing trials with oral paliperidone, the highest estimated ingestion was 405 mg. Observed signs and symptoms included extrapyramidal symptoms and gait unsteadiness. Other potential signs and symptoms include those resulting from an exaggeration of paliperidone's known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, and QT prolongation.

Paliperidone is the major active metabolite of risperidone. Overdose experience reported with risperidone can be found in the OVERDOSAGE section of the risperidone package insert.

Management of Overdose: There is no specific antidote to paliperidone, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Consideration should be given to the prolonged-release characteristics of INVEGA® SUSTENNA™ and the long apparent half-life of paliperidone when assessing treatment needs and recovery. Multiple drug involvement should also be considered.

In case of acute overdose, establish and maintain an airway and ensure adequate oxygenation and ventilation. The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of paliperidone. Similarly the alpha-blocking properties of bretylium might be additive to those of paliperidone, resulting in problematic hypotension.

Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of paliperidone-induced alpha blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered.

Manufactured by:
Janssen Pharmaceutica N.V.
Beerse, Belgium

Manufactured for:
Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Titusville, NJ 08560

©Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009

Revised: July 2009

363488
CNS Spectrums is now accepting submissions of the following manuscripts via ScholarOne Manuscripts web-based peer-review platform:

- Review articles
- Original research
- Letters to the Editor

Examples of topics and types of articles of interest include:

- Clinical interface of psychiatry and neurology.
- Neurology and neuropsychiatry in a clinical setting addressing spectrum disorders.
- Manuscripts geared toward deepening the clinician's understanding of neuropsychiatric disorders and treatments.
- Applications of psychopharmacology and pharmacokinetics across the neuropsychiatric spectrum.
- Review articles containing critical appraisal of the literature, with synthesis of the strengths and/or weaknesses of cited research. Review articles contextualizing the neuropsychiatric problem/topic.

Authors: Please submit manuscripts by visiting the following CNS Spectrums link: http://mc.manuscriptcentral.com/cnsspectr.

Author Guidelines can be found at www.cnsspectrums.com/aspx/authorguidelines.aspx.

CNS Spectrums has the largest circulation in the nation among peer-reviewed, indexed neuroscience journals with a monthly readership of 50,000 neurologists and psychiatrists.

If you have any questions about submitting manuscripts through the ScholarOne Manuscripts platform, please e-mail Lisa Arrington, Senior Acquisitions Editor, lla@mblcommunications.com.

www.cnsspectrums.com
and reports that emphasize the profound diagnostic and physiologic connections disease, illness, or trauma.

MISSION STATEMENT

CNS Spectrums is a monthly index Medicus/MEDLINE journal designed to bridge the clinical information needs of 50,000 psychiatrists and neurologists. Introduced in 1996, CNS Spectrums reaches more physicians than any other indexed, peer-reviewed neuroscience journal in the world.

In addition, the 2007 ISI Journal Citation Reports’ Impact Factor for CNS Spectrums is 2.222. The Impact Factor is based on a total of 1,179 citations.

EDITORIAL AND PEER REVIEW

CNS Spectrums SISSN 1092-8529 is published monthly by MBL Communications, Inc., 333 Hudson Street, 7th Floor, New York, NY 10013. Periodicals postage paid at New York, NY, and additional mailing offices. POSTMASTER: Send address changes to CNS Spectrums, 333 Hudson St., 7th Floor, New York, NY 10013.

CNS Spectrums is a monthly index Medicus/MEDLINE journal designed to bridge the clinical information needs of 50,000 psychiatrists and neurologists. Introduced in 1996, CNS Spectrums reaches more physicians than any other indexed, peer-reviewed neuroscience journal in the world.

In addition, the 2007 ISI Journal Citation Reports’ Impact Factor for CNS Spectrums is 2.222. The Impact Factor is based on a total of 1,179 citations.

EDITORIAL CONTENT: CNS Spectrums will consider and encourage the following types of articles for publication: Original Research—Methodologically and scientifically sound original data; Reviews—Comprehensive articles summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; Letters to the Editor—Approved letters will be edited for style, clarity, and size.

PEER REVIEW: Articles appearing in CNS Spectrums are peer reviewed by two independent reviewers using the ScholarOne Manuscripts web platform.

SUBMITTING MANUSCRIPTS TO CNS SPECTRUMS: All submissions to CNS Spectrums, including articles and Letters to the Editor, should be submitted through the following ScholarOne Manuscripts web site: http://mc.manuscriptcentral.com/cnsspectrums

INSTRUCTIONS FOR AUTHORS: Author Guidelines are available at www.cnsspectrums.com/asp/authorguidelines.aspx

INDEXING: CNS Spectrums is indexed in the Index Medicus database, EMBASE, and is available on MEDLINE under the citation CNS Spectrums. The full text article Link-Out feature is also available.

SUBSCRIPTIONS, BACK ISSUES, AND ADDRESS CHANGES

ANNUAL SUBSCRIPTION RATES - 2010

<table>
<thead>
<tr>
<th></th>
<th>United States</th>
<th>International</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals</td>
<td>$140</td>
<td>$175 (US)</td>
</tr>
</tbody>
</table>

Institutional Pricing: Please contact cdn@mlbcommunications.com For subscriptions: Tel 212-328-0800; Fax 212-328-0600; Web: www.cnsspectrums.com.

SINGLE COPIES AND BACK ISSUES: To order a single copy or a back issue, please visit https://secure.mlbcmt.com/CNS/Spectrums.aspx/BackIssues.aspx. Issues are $20 per copy (including all domestic shipping costs).

ADDRESS CHANGES: In order to change your address, please visit www.cnsspectrums.com/asp/ChangeMyAddress.aspx. Address changes take 4-6 weeks to verify. You can also fax a letter to 212-328-0600 or mail a letter to:

CNS Spectrums
Attn: Subscriptions
333 Hudson St., 7th Floor
New York, NY 10013

ATTENTION AAMA MEMBERS: To change your address, you must do so through the AAMA since they are the source of our subscription database. We cannot process the change for you. Please call the AAMA at 800-292-3271.

ONLINE ACCESS: CNS Spectrums’ content is available online at www.cnsspectrums.com.

Follow us on Twitter at twitter.com/cnsspectrums.

COPYRIGHT/FINANCIAL DISCLOSURE

COPYRIGHT: Materials are accepted for exclusive publication in CNS Spectrums and become the property of CNS Spectrums. Permission to reproduce material must be obtained from the publisher.

DISCLOSURE OF COMMERCIAL AND NON-COMMERCIAL INTERESTS: Authors must include a statement about all forms of support, including grant and pharmaceutical support, affiliations, and honoraria received for past and present material. Such information may, at the editor’s discretion, be shared with reviewers. If the article is accepted for publication, all relevant disclosure information is listed.

PERMISSIONS REQUESTS

REQUESTS FOR PERMISSIONS MAY BE SUBMITTED VIA THE FOLLOWING METHODS:

• If you would like to electronically obtain permission to use materials (tables, figures, etc.) presented in CNS Spectrums, please visit http://www.copyright.com and enter “CNS Spectrums”. You may also e-mail cdn@mlbcommunications.com

• If you would like to submit a written permission request, please fax or mail to the following number and/or address:
  Fax: 212-328-0600
  Mail: CNS Spectrums
  ATTN: Permissions
  333 Hudson St., 7th Floor
  New York, NY 10013

• Permission will not be granted until the article in which the material appears has been published in CNS Spectrums.

• In order to complete the request, we will need the following information: Article Title, Author(s), Journal Citation (Year; Volume; Issue Number; Page Range), the Copyrighted item to be Used, and Description of Intended Use/Audience. Please include your Name, Company, Address, Phone/Fax Numbers, and E-mail Address.

• If the permission request is approved, the journal should be cited as “CNS Spectrums” followed by the article’s numerical citation.

• Use of the full text of material published in CNS Spectrums is not permitted on other Web sites.

EMBARGO

All materials published in CNS Spectrums are embargoed until the 15th of the month of publication.

REPRINTS

For bulk reprint purchases, please contact Christopher Naccari at cdn@mlbcommunications.com or go to www.cnsspectrums.com/asp/Reprints.aspx. Please include: Article Title; Author(s); Journal Citation; Year; Volume; Issue Number; and Quantity.

ADVERTISING

CONTACTS:

• Print Ads: Christopher Naccari, cdn@mlbcommunications.com

• Classifieds: Kimberly Schneider, ks@mlbcommunications.com

• Web Ads: Bill Jennings, bill@goodhealthadvertising.com

MEDIA KITS: Media Kits are available upon request in print or PDF formats. Please e-mail Kimberly Schneider, ks@mlbcommunications.com.

DISCLAIMER AND COPYRIGHT

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., CNS Spectrums, LLC, or the editorial advisory board. The publisher is not guaranteeing or warranting or assuming any liability or responsibility for or with respect to and expressly disclaims any liability or responsibility for or with respect to this publication or the information contained therein.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use of misuse of information contained herein. The information contained in CNS Spectrums is intended for general educational and informational purposes; it is not intended as the sole basis upon which any action is to be recommended or taken.

Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation. The readers of this publication use and evaluate the information contained in this publication at their own risk.

Copyright © 2010 by MBL Communications, Inc. CNS Spectrums is a registered trademark of CNS Spectrums, LLC, New York, N.Y. Permission to reproduce articles in whole or part must be obtained in writing from the publisher. Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form. Reproduction without permission is prohibited.
Editorial

210 One Size Fits None? Treatment Algorithms and Guidelines in Psychiatry and Neurology
Andrew A. Nierenberg, MD, Massachusetts General Hospital, Harvard Medical School

Letter to the Editor

215 Pulvinar Sign in Wernicke’s Encephalopathy
Christian Schmidt, MD, Goettingen Medical School; Steffen Plickert, MD, St. Katharinen Hospital; David Summers, MD, University of Edinburgh Medical School; and Inga Zerr, MD, PhD, German National Reference Center for the Surveillance of Prion Diseases.

Trends in Psychopharmacology

220 Methylated Spirits: Epigenetic Hypotheses of Psychiatric Disorders
Stephen M. Stahl, MD, PhD, University of California-San Diego

Case Report

231 Cerebrotendinous Xanthomatosis Presenting with Severe Externalized Disorder: Improvement After One Year of Treatment with Chenodeoxycholic Acid
Olivier Bonnot, MD, PhD, Groupe Hospitalier Pitie Salpetriere; Matthew J. Fraidakis, MD, PhD, Karolinska Institute; Raffaella Lucanto, PhD, Groupe Hospitalier Pitie Salpetriere; Dominique Chauvin, PhD, Groupe Hospitalier Pitie Salpetriere; Nathalie Kelley, PhD, Groupe Hospitalier Pitie Salpetriere; Monique Plaza, PhD, Groupe Hospitalier Pitie Salpetriere; Odile Dubourg, MD, PhD, Groupe Hospitalier Pitie Salpetriere; Olivier Lyon-Caen, MD, Groupe Hospitalier Pitie Salpetriere; Frédéric Sedel, MD, PhD, Groupe Hospitalier Pitie Salpetriere; and David Cohen MD, PhD, Groupe Hospitalier Pitie Salpetriere.

Review Article

238 Duration of Untreated Psychosis and Duration of Untreated Illness: New Vistas
Bernardo Dell’Osso, MD and A. Carlo Altamura, MD, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico.

Original Research

248 Assessing Effects of Treatment With Lisdexamfetamine Dimesylate for Pediatric ADHD Using a Parental Survey
Donna Antonucci, MD, Private Practice; Craig Kunins, MD, Center for Attention, Mood, and Behavior; Michael Manos, PhD, Children’s Hospital, Cleveland Clinic; Frank A. López, MD, Children’s Developmental Center; and Donna L. Kerney, PhD, InfoMedics.

258 Clinical Features and Treatment Characteristics of Compulsive Hoarding in Japanese Patients with Obsessive-Compulsive Disorder
Hisato Matsunaga, MD, PhD, Kazuhsa Hayashida, MD, Nobuo Kiriike, MD, PhD, Toshihiko Nagata, MD, PhD, Osaka City University; and Dan J. Stein, MD, PhD, University of Cape Town.

CME Expert Panel Supplement

Practical Dosing Strategies in the Treatment of Schizophrenia
Delbert Robinson, MD, Christoph U. Correll, MD, and John M. Kane, MD.
PBA:

• Is associated with neurologic diseases such as MS, ALS, Parkinson’s disease, dementias including Alzheimer’s disease, and neurologic injuries such as stroke and TBI.1,2

• It is hypothesized that these neurologic diseases and injuries impact the excitatory action of glutamate, leading to excessive glutamatergic signaling and increased electrical activity in neurons.3-6

PBA:

• Is a distinct neurologic disorder of affect characterized by involuntary episodes of motor expression of emotion, such as laughing, crying, or related facial features.7

• PBA is surprisingly prevalent, affecting millions of patients and caregivers in the United States alone.8-12

• The disorder is also commonly known as emotional lability, pathologic laughing and crying, and emotional incontinence.1

PBA:

• Can significantly impact patients and caregivers.6 The symptoms of PBA can be severe, with persistent and unremitting episodes.13 Involuntary crying or laughing may lead to embarrassment, anxiety, and depression, and result in social isolation.14-16

• Addressing PBA can help improve the lives of patients and their families and caregivers,6 thereby reducing its physical, emotional, and social impact

For more information, please visit www.PBAinfo.org

References: